USRE29836E - 4-Hydroxy-3-(3-isoxazolylcarbamoyl)-2H-1,2-benzothiazine 1,1-dioxides and process for their production - Google Patents

4-Hydroxy-3-(3-isoxazolylcarbamoyl)-2H-1,2-benzothiazine 1,1-dioxides and process for their production Download PDF

Info

Publication number
USRE29836E
USRE29836E US05/840,929 US84092977A USRE29836E US RE29836 E USRE29836 E US RE29836E US 84092977 A US84092977 A US 84092977A US RE29836 E USRE29836 E US RE29836E
Authority
US
United States
Prior art keywords
methyl
compound
benzothiazine
hydroxy
isoxazolylcarbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/840,929
Inventor
Harold Zinnes
Martin L. Schwartz
John Shavel, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of USRE29836E publication Critical patent/USRE29836E/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms

Definitions

  • the present invention relates to 4-hydroxy-3-(3-isoxazolylcarbamoyl)-2H-1,2-benzothiazine, 1,1-Dioxides having the following structural formula: ##STR2## wherein R 1 is hydrogen or methyl and R 2 , and R 3 are hydrogen or alkyl having from 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl and the like.
  • the present invention also includes within its scope the corresponding alkali metal, alkaline earth and amine salts.
  • the compounds of this invention are useful as antiinflammatory agents, antipyretics, and analgesics in several mammalian species.
  • rats When administered orally to rats at a dose of 10-200 mg./kg., they are able to cause reduction in swelling of the paw induced by injection into the foot pads of an irritant such as carrageenin.
  • Oral doses of 25-100 mg./kg. are sufficient to inhibit yeast induced hyperthermia in the rat.
  • these compounds are indicated in conditions such as pain resulting from arthritis, bursitis and the like.
  • a daily dosage regimen of about 0.5 grams to about 2 grams in several divided doses is recommended for a mammal weighing about 70 kg. body weight to relieve the pain and swelling associated with these conditions.
  • These compounds are administered either orally or by injection.
  • these compounds are formulated into dosage forms such as tablets or syrups by blending with an inert pharmaceutical carrier such as lactose or simple syrup by methods well known to the pharmacists art.
  • dosage forms such as tablets or syrups by blending with an inert pharmaceutical carrier such as lactose or simple syrup by methods well known to the pharmacists art.
  • inert pharmaceutical carrier such as lactose or simple syrup
  • injectionable dosage forms they are formulated with vehicles such as water, peanut oil, sesame oil, and the like.
  • the active ingredient is from about 0.5 grams to 1 gram per dosage unit.
  • starting compound II is refluxed with 3-aminoisoxazole III in an inert solvent such as xylene.
  • the reactants are refluxed in the presence of a molecular sieve which promote the desired reaction by removing the alcohol which is formed as a by-product.
  • a molecular sieve which promote the desired reaction by removing the alcohol which is formed as a by-product.
  • the use of molecular sieves results in a more convenient and practical process in that lengthy distillation to remove the alcohol is no longer required.
  • the reaction is carried out in a Soxhlet apparatus with the molecular sieves contained in the thimble.
  • molecular sieves which can be used in this process, are commercially available molecular sieves under the trade name Linde type 4A molecular sieve from Matheson Coleman & Bell Company. See also Fieser & Fieser, "Reagents for Organic Synthesis," Vol. 1.
  • the starting material II are known compounds and they are prepared in accordance with the description in U.S. Pat. No. 3,501,466.
  • the corresponding salts with metal or with amine are prepared by treating the above compounds with the desired base e.g. sodium alkoxide, potassium alkoxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, pyrrolidine and the like by conventional procedures.
  • the desired base e.g. sodium alkoxide, potassium alkoxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, pyrrolidine and the like by conventional procedures.
  • a 2-unsubstituted derivative of structure IV is reacted with sodium hydride in dimethylformamide and the resulting anion is treated with methyl iodide.
  • methylation takes place solely at the 2-position. Dilution of the reaction mixture with water results in the precipitation of the crystalline product I in high yield and a high state of purity.
  • the corresponding sodium salt was prepared by treating the above compound with sodium hydroxide which has the following structural formula: ##STR6##
  • the sodium salt after recrystallization from ethanol has m.p. 270-272° dec.

Abstract

Compounds having the following structural formula are disclosed: ##STR1## wherein R1 is hydrogen or methyl and R2, and R3 are hydrogen or alkyl. These compounds are useful as anti-inflammatory agents, antipyretics, analgesics.

Description

.[.This application is a continuation-in-part of our copending application U.S. Ser. No. 33,821, filed Feb. 20, 1973, which in turn is a divisional of U.S. Ser. No. 119,967 filed Mar. 1, 1971, now abandoned..].
.Iadd.This application is a reissue of U.S. Pat. No. 3,822,858, filed as U.S. Ser. No. 356,026 on Apr. 30, 1973, which is a continuation-in-part of U.S. Ser. No. 333,821, filed Feb. 20, 1973, now U.S. Pat. No. 3,816,828, which in turn is a divisional of U.S. Ser. No. 119,967, filed Mar. 1, 1971, now U.S. Pat. No. 3,787,324. .Iaddend.
The present invention relates to 4-hydroxy-3-(3-isoxazolylcarbamoyl)-2H-1,2-benzothiazine, 1,1-Dioxides having the following structural formula: ##STR2## wherein R1 is hydrogen or methyl and R2, and R3 are hydrogen or alkyl having from 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl and the like.
The present invention also includes within its scope the corresponding alkali metal, alkaline earth and amine salts.
The compounds of this invention are useful as antiinflammatory agents, antipyretics, and analgesics in several mammalian species. When administered orally to rats at a dose of 10-200 mg./kg., they are able to cause reduction in swelling of the paw induced by injection into the foot pads of an irritant such as carrageenin. Therapeutically or prophylactically administered orally at a dose of 15-200 mg./kg., the compounds inhibit adjuvant induced polyarthritis in the rat. Oral doses of 25-100 mg./kg. are sufficient to inhibit yeast induced hyperthermia in the rat. At oral doses of 25-200 mg./kg. they exhibit a significant analgesic effect as determined by the phenylquinone writhing procedure in mice.
Generally speaking, these compounds are indicated in conditions such as pain resulting from arthritis, bursitis and the like. A daily dosage regimen of about 0.5 grams to about 2 grams in several divided doses is recommended for a mammal weighing about 70 kg. body weight to relieve the pain and swelling associated with these conditions. These compounds are administered either orally or by injection.
In order to use these compounds, they are formulated into dosage forms such as tablets or syrups by blending with an inert pharmaceutical carrier such as lactose or simple syrup by methods well known to the pharmacists art. For injectionable dosage forms, they are formulated with vehicles such as water, peanut oil, sesame oil, and the like. In these dosage forms, the active ingredient is from about 0.5 grams to 1 gram per dosage unit.
According to the present invention, the above compounds are prepared by a reaction scheme as follows: ##STR3##
Generally speaking, starting compound II is refluxed with 3-aminoisoxazole III in an inert solvent such as xylene. In a preferred embodiment of the present invention, the reactants are refluxed in the presence of a molecular sieve which promote the desired reaction by removing the alcohol which is formed as a by-product. The use of molecular sieves results in a more convenient and practical process in that lengthy distillation to remove the alcohol is no longer required. Typically the reaction is carried out in a Soxhlet apparatus with the molecular sieves contained in the thimble.
Examples of the molecular sieves, which can be used in this process, are commercially available molecular sieves under the trade name Linde type 4A molecular sieve from Matheson Coleman & Bell Company. See also Fieser & Fieser, "Reagents for Organic Synthesis," Vol. 1.
The starting material II are known compounds and they are prepared in accordance with the description in U.S. Pat. No. 3,501,466.
Starting compound 3-aminoisoxazole is prepared in accordance with the description in Chem. Pharm. Bull. 14, 1277 (1969). The starting compound 3-amino-5-methylisoxazole is commercially available from Hoffmann-La Roche. It is prepared in accordance with the description set forth in the Netherlands Pat. No. 6,511,924, issued Mar. 15, 1966.
The corresponding salts with metal or with amine are prepared by treating the above compounds with the desired base e.g. sodium alkoxide, potassium alkoxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, pyrrolidine and the like by conventional procedures.
According to a further feature of this invention, a 2-unsubstituted derivative of structure IV is reacted with sodium hydride in dimethylformamide and the resulting anion is treated with methyl iodide. Under the conditions described, methylation takes place solely at the 2-position. Dilution of the reaction mixture with water results in the precipitation of the crystalline product I in high yield and a high state of purity. This reaction is as follows: ##STR4##
In order to further illustrate the practice of this invention, the following examples are included. All temperatures are given in degrees centigrade.
EXAMPLE I ##STR5## 4-Hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-Dioxide
A mixture of 40.5 g. (0.15 mole) of 3-carbethoxy-4-hydroxy-2-methyl-2H-1,2-benzothiazine 1,1-dioxide, 20.6 g. (0.21 mole) of 3-amino-5-methylisoxazole, and 2500 ml. of xylene was refluxed for 24 hr. in a Soxhlet apparatus, the thimble of which contained 60 g. of Linde type 4A molecular sieve. The mixture was cooled to 25° and the resulting crystalline precipitate was collected and washed with ether to give 44 g. of crude product. Recrystallization from 1600 ml. of 1,4-dioxan gave 34.7 of material, m.p. 265-271° dec.
Anal.--Calcd. for C14 H13 N3 O5 S: C, 50.14; H, 3.91; N, 12.53; S, 9.56. Found: C, 50.33; H, 3.88; N, 12.30; S, 9.49.
The corresponding sodium salt was prepared by treating the above compound with sodium hydroxide which has the following structural formula: ##STR6## The sodium salt after recrystallization from ethanol has m.p. 270-272° dec.
Anal.--Calcd. for C14 H12 N3 O5 SNa: C, 47.06; H, 3.39; N, 11.76; S, 8.97. Found: C, 47.09; H, 3.69; N, 11.50; S, 8.81.
EXAMPLE II ##STR7## 4-Hydroxy-3-(3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-Dioxide
A mixture of 4.15 g. (0.0155 mole) of 3-carbethoxy-4-hydroxy-2-methyl-2H-1,2-benzothiazine 1,1-dioxide, 1.3 g. (0.0155 mole) of 3-aminoisoxazole, and 500 ml. of xylene was refluxed for 24 hr. in a Soxhlet apparatus, the thimble of which contained 10 g. of Linde 4A molecular sieve. The mixture was cooled to 25° and the resulting crystalline precipitate was collected and washed with ether to give 3.2 g. of product, m.p. 235-240° dec. Recrystallization from 175 ml. of ethyl acetate gave 1.6 g. of material, m.p. 237-240° dec.
Anal.--Calcd. for C13 H11 N3 O5 S: C, 48.60; H, 3.45; N, 13.08; S, 9.98. Found: C, 48.77; H, 3.44; N, 12.86; S, 9.85.
EXAMPLE III ##STR8## 4-Hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2H-1,2-benzothiazine 1,1-Dioxide
A mixture of 15.3 g. (0.06 mole) of 3-carbethoxy-4-hydroxy-2-methyl-2H-1,2-benzothiazine 1,1-dioxide, 5.9 g. (0.06 mole) of 3-amino-5-methylisoxazole, and 800 ml. of xylene was refluxed for 24 hr. in a Soxhlet apparatus, the thimble of which contained 20 g. of Linde type 4A molecular sieve. The mixture was cooled to 25° and the resulting precipitate was collected and washed with ether to give 11.5 g. of crude product, m.p. 242-248° dec. Recrystallization from 300 ml. of 1,4-dioxan gave 11.2 g. of crystalline product, m.p. 254-257° dec.
Anal.--Calcd. for C13 H11 N3 O5 S: C, 48.60; H, 3.45; N, 13.08; S, 9.98. Found: C, 48.67; H, 3.44; N, 12.91; S, 10.23.
EXAMPLE IV ##STR9##
To a mixture of 0.01 mole (as a 57% dispersion in mineral oil) and 3.21 g. (0.01 mol) of Compound IV was added 20 ml. of dry dimethylformamide. The mixture was stirred for one hour during which hydrogen evolved and the dark brown anion formed. A solution of 1.42 g. (0.01 mol) of methyl iodide in dimethylformamide was added, the reaction mixture was stirred at 60° for 4 hours, and then at 25° for 16 hours. It was diluted with 20 ml. of water and stirred for one hour. The resulting precipitate was collected, washed with two 10 ml. portions of dimethylformamide and one 20 ml. portion of methanol and air dried. Yield: 2.7 g. of white solid, m.p. 259-262° dec.

Claims (4)

    We claim: .[.1. A compound of the formula: ##STR10## wherein R1 is hydrogen or methyl and R2, and R3 are hydrogen or alkyl having 1 to 7 carbon atoms, or its corresponding alkali
  1. metal, akaline earth and amine salts..]. .[.2. A compound according to claim 1 which is 4-Hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-Dioxide..]. .[.3. A compound according to claim 1 which is 4-Hydroxy-3-(3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-Dioxide..]. .[.4. A compound according to claim 1 which is 4-Hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2H-1,2-benzothiazine 1,1-Dioxide..]. pg,5 .[.5. A process for production of the compound of claim 1 which comprises refluxing together a compound of Structure II: ##STR11## in which R4 is lower alkyl with a compound of Structure III: ##STR12## in an inert solvent in the presence of a molecular sieve adapted to remove
  2. the by-product alcohol formed..]. .[.6. A process for the production of the compound of claim 2 which comprises treating a compound of the formula: ##STR13## with sodium hydride in dimethylformamide, treating the resulting anion with methyl iodide; adding water to the reaction mixture; and recovering
  3. compound I as a precipitate..]. .Iadd. 7. A process for the production of a compound of the formula I: ##STR14## wherein R1 is hydrogen or methyl and R2 and R3 are hydrogen or alkyl having 1 to 7 carbon atoms or its corresponding alkali metal, alkaline earth and amine salts; which comprises refluxing together a compound of the formula II: ##STR15## in which R4 is lower alkyl with a compound of the formula III: ##STR16## in an inert solvent in the presence of a molecular sieve adapted to remove
  4. the by-product alcohol formed. .Iaddend..Iadd. 8. A process for the production of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-dioxide which comprises treating a compound of the formula IV: ##STR17## with sodium hydride in dimethylformamide, treating the resulting anion with methyl iodide; adding water to the reaction mixture; and recovering 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-dioxide as a precipitate. .Iaddend.
US05/840,929 1971-03-01 1977-10-11 4-Hydroxy-3-(3-isoxazolylcarbamoyl)-2H-1,2-benzothiazine 1,1-dioxides and process for their production Expired - Lifetime USRE29836E (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11996771A 1971-03-01 1971-03-01
US00333821A US3816628A (en) 1971-03-01 1973-02-20 4-hydroxy-3-(3-isoxazolocarbamyl)-2h-1,2-benzothiazine 1,1-dioxides to treat inflammatory fever and pain conditions
US00356026A US3822258A (en) 1971-03-01 1973-04-30 4-hydroxy-3-(3-isoxazolylcarbamoyl)-2h-1,2-benzothiazine 1,1-dioxides and process for their production

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US00333821A Continuation-In-Part US3816628A (en) 1971-03-01 1973-02-20 4-hydroxy-3-(3-isoxazolocarbamyl)-2h-1,2-benzothiazine 1,1-dioxides to treat inflammatory fever and pain conditions
US00356026A Reissue US3822258A (en) 1971-03-01 1973-04-30 4-hydroxy-3-(3-isoxazolylcarbamoyl)-2h-1,2-benzothiazine 1,1-dioxides and process for their production

Publications (1)

Publication Number Publication Date
USRE29836E true USRE29836E (en) 1978-11-14

Family

ID=27382407

Family Applications (4)

Application Number Title Priority Date Filing Date
US00119967A Expired - Lifetime US3787324A (en) 1971-03-01 1971-03-01 4-hydroxy-3-(3-isoxazolocarbamyl)-2h-1,2-benzothiazine 1,dioxides and process for their production
US00333821A Expired - Lifetime US3816628A (en) 1971-03-01 1973-02-20 4-hydroxy-3-(3-isoxazolocarbamyl)-2h-1,2-benzothiazine 1,1-dioxides to treat inflammatory fever and pain conditions
US00356026A Expired - Lifetime US3822258A (en) 1971-03-01 1973-04-30 4-hydroxy-3-(3-isoxazolylcarbamoyl)-2h-1,2-benzothiazine 1,1-dioxides and process for their production
US05/840,929 Expired - Lifetime USRE29836E (en) 1971-03-01 1977-10-11 4-Hydroxy-3-(3-isoxazolylcarbamoyl)-2H-1,2-benzothiazine 1,1-dioxides and process for their production

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US00119967A Expired - Lifetime US3787324A (en) 1971-03-01 1971-03-01 4-hydroxy-3-(3-isoxazolocarbamyl)-2h-1,2-benzothiazine 1,dioxides and process for their production
US00333821A Expired - Lifetime US3816628A (en) 1971-03-01 1973-02-20 4-hydroxy-3-(3-isoxazolocarbamyl)-2h-1,2-benzothiazine 1,1-dioxides to treat inflammatory fever and pain conditions
US00356026A Expired - Lifetime US3822258A (en) 1971-03-01 1973-04-30 4-hydroxy-3-(3-isoxazolylcarbamoyl)-2h-1,2-benzothiazine 1,1-dioxides and process for their production

Country Status (5)

Country Link
US (4) US3787324A (en)
AU (1) AU456075B2 (en)
CA (1) CA978187A (en)
FR (1) FR2128371B1 (en)
GB (1) GB1323283A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002709A2 (en) 1996-07-16 1998-01-22 Casull Richard J Extractor, cartridge, and receiver for a firearm

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868367A (en) * 1974-04-11 1975-02-25 Warner Lambert Co 4-Hydroxy-3-(5-isoxazolylcarbamoyl)-2H-1,2-benzothiazine 1,1-dioxides
US3957772A (en) * 1975-05-21 1976-05-18 Warner-Lambert Company Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazine 1,1-dioxide
US3987038A (en) * 1975-05-21 1976-10-19 Warner-Lambert Company Process for the preparation of {1-[5-(4-hydroxy-2H-1,2-benzothiazin-3-yl)-1,2,4-oxadiazol-3-yl]methyl}ethanone S,S-dioxide
US4024136A (en) * 1975-06-20 1977-05-17 Warner-Lambert Company Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-dioxide
LU78009A1 (en) 1977-08-22 1979-05-23 Hoffmann La Roche METHOD FOR PRODUCING THIAZINE DERIVATIVES
AU518216B2 (en) 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
US4289879A (en) * 1980-09-29 1981-09-15 Pfizer Inc. Synthetic method and intermediate for piroxicam
US4474955A (en) * 1981-06-17 1984-10-02 Vincenzo Iannella Process for preparing 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-[N-(2-pyridinyl)carboxamide]-1,1-dioxide, and its phosphoric ester
EP0082217A1 (en) * 1981-12-23 1983-06-29 Ciba-Geigy Ag Ammonium salts, process for their preparation, pharmaceutical preparations containing them and their use
DE3212485A1 (en) * 1982-04-03 1983-10-13 Gödecke AG, 1000 Berlin METHOD FOR PRODUCING 4-HYDROXY-3- (HETEROCYCLOCARBAMOYL) -2H-1,2-BENZOTHIAZINE-1,1-DIOXIDES
CA1197244A (en) * 1982-04-16 1985-11-26 Medichem, S.A. Process for the preparation of 4-hydroxy-2-methyl-2h- 1,2-benzothiazine-3-carboxamide-1,1-dioxides
US4489077A (en) * 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US4551452A (en) * 1983-12-21 1985-11-05 Pfizer Inc. Anti-inflammatory 2-methyl-2H-1,2-benzo-(or -thieno-)thiazine-3-carboxamide 1,1-dioxide derivatives, compositions, and method of use therefor
DE3346526C2 (en) * 1983-12-22 1986-12-11 A. Nattermann & Cie GmbH, 5000 Köln Pharmaceutical preparation for the therapeutic treatment of rheumatic diseases
JPS60184077A (en) * 1984-02-23 1985-09-19 フアイザー・インコーポレーテツド Antiinflammatory oxime precursor drug
US4656265A (en) * 1984-06-21 1987-04-07 Pfizer Inc. Cyclic prodrugs of antiinflammatory oxicams
US4623486A (en) * 1985-05-29 1986-11-18 Pfizer Inc. [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity
US4610982A (en) * 1985-06-03 1986-09-09 Pfizer Inc. Anti-inflammatory benzo- and thieno-1,2-thiazine-3-carboxamide 1,1-dioxide derivatives, compositions, and method of use therefor
US4829062A (en) * 1986-05-16 1989-05-09 Pfizer Inc. Benzothiazine dioxide derivatives
JP3016587B2 (en) * 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク Combination of non-steroidal anti-inflammatory drug and tetracycline
US5308839A (en) * 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
CN101522692A (en) 2006-10-11 2009-09-02 于崇曦 Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate
PL2170826T3 (en) 2007-06-04 2022-09-05 Techfields Inc Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
CN108191846B (en) 2008-12-04 2021-08-20 于崇曦 High penetration composition and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3646021A (en) * 1970-07-16 1972-02-29 Warner Lambert Pharmaceutical 4 - hydroxy - 3 - furylcarbamyl - 2h - 1 2-benzothiazine 1 1-dioxides and process thereof
US3704298A (en) * 1971-06-22 1972-11-28 Warner Lambert Co 4-acyloxy-3-(2-isoxazolocarbamyl)-2h-1,2-benzothiazine 1,1-dioxides
US3714155A (en) * 1971-09-27 1973-01-30 Warner Lambert Co 4-hydroxy-2,n-dimethyl-2h-1,2-benzothiazine-3-carboxanilide1,1-dioxide and process therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3501466A (en) * 1967-11-30 1970-03-17 Mcneilab Inc 3-carbamoyl and 3-alkoxycarbonyl benzothiazine-1,1-dioxides
US3591584A (en) * 1968-08-27 1971-07-06 Pfizer Benzothiazine dioxides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3646021A (en) * 1970-07-16 1972-02-29 Warner Lambert Pharmaceutical 4 - hydroxy - 3 - furylcarbamyl - 2h - 1 2-benzothiazine 1 1-dioxides and process thereof
US3704298A (en) * 1971-06-22 1972-11-28 Warner Lambert Co 4-acyloxy-3-(2-isoxazolocarbamyl)-2h-1,2-benzothiazine 1,1-dioxides
US3714155A (en) * 1971-09-27 1973-01-30 Warner Lambert Co 4-hydroxy-2,n-dimethyl-2h-1,2-benzothiazine-3-carboxanilide1,1-dioxide and process therefor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002709A2 (en) 1996-07-16 1998-01-22 Casull Richard J Extractor, cartridge, and receiver for a firearm

Also Published As

Publication number Publication date
GB1323283A (en) 1973-07-11
AU456075B2 (en) 1972-11-21
DE2208351A1 (en) 1972-09-14
FR2128371B1 (en) 1975-10-10
US3822258A (en) 1974-07-02
DE2208351B2 (en) 1976-09-16
FR2128371A1 (en) 1972-10-20
AU3903872A (en) 1973-08-23
CA978187A (en) 1975-11-18
US3787324A (en) 1974-01-22
US3816628A (en) 1974-06-11

Similar Documents

Publication Publication Date Title
USRE29836E (en) 4-Hydroxy-3-(3-isoxazolylcarbamoyl)-2H-1,2-benzothiazine 1,1-dioxides and process for their production
CA1128526A (en) 3,4-diarylisoxazol-5-acetic acids
HU193161B (en) Process for preparing new n-alkyl-norscopines
JPS582936B2 (en) 5↓-Production method of aroylpyrroleacetic acid and its salts
US5116995A (en) Carbazole compounds
US7902357B2 (en) Process for the preparation of delmopinol and derivatives thereof
CS241016B2 (en) Method of new n-(2-(or)pyrrolidinylmethyl)-benzamides production substituted in positions 2,3,4,5,6
US4018762A (en) Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-dioxide
JPS5922711B2 (en) Method for producing benzoxazolinone derivatives
CA1156235A (en) 1-(8-quinolyl)-2-pyrrolidinone
JPS60120865A (en) Novel carbostyryl derivative
US3073826A (en) 3-pyrrolidylmethyl-4-quinazolones
US4076722A (en) Composition containing alkyl 2-{[({[(5-methyl-3-isoxazolyl)-amino]carbonyl}methyl)amino]sulfonyl}benzoate and an alkali metal alkoxide of a lower alcohol in an inert solvent
Santilli et al. 8, 9, 10, 11-Tetrahydro-12H-benzo [5, 6] quinoxalino-[2, 3-e][1, 4] diazepin-12-ones. Examples of a New Heterocyclic Ring System
EP0085866B1 (en) Derivatives of benzo-1,2-thiazine-1,1-dioxide, a process for their preparation and pharmaceutical compositions containing the same
US4767767A (en) 2-pyrrolidinylethyl-2-(7-trifluoromethyl-4-quinolyl-aminobenzoate having analgesic, antipyretic and anti-inflammatory activities
CS196445B2 (en) Method of producing novel derivatives of indolyl-acetic acid and salts of the same
US3375278A (en) 1, 1-bis(biphenylyl)-2-methyl-3-tertiary aminopropanols and salts thereof
US3185702A (en) Basic esters of 3-aryl-3-pyrrolidinols
US4041042A (en) Intermediate composition
JPH06340622A (en) Production of benzylsuccinic acid derivative and intermediate for its synthesis
JPS6045577A (en) 2-azabicylo(2,2,2)octane derivative
JPS61178999A (en) Organogold compound
JPH0357896B2 (en)
KR800000408B1 (en) Process for preparing 4-hydroxy-2h-naphtho(2,1-e)-1,2-thiazine-3-carboxamide-1,1-dioxides